key: cord-0798403-il60u8ao authors: Xiang, Xiao Gang; Xie, Qing title: IL‐35: A potential therapeutic target for controlling hepatitis B virus infection date: 2015-01-28 journal: J Dig Dis DOI: 10.1111/1751-2980.12218 sha: 674b722b3be451081f16170c024d3da3a35a74cb doc_id: 798403 cord_uid: il60u8ao Interleukin (IL)‐35, a recently identified cytokine of the IL‐12 family, is a potent immunosuppressive cytokine secreted by regulatory T (Treg) cells and the newly reported regulatory B (Breg) cells. IL‐35 functions as a crucial immunosuppressive factor in immune‐mediated diseases, and the predominant mechanism of suppression is its ability to suppress T cell proliferation and effector functions. The pathogenic processes of the non‐cytopathic hepatitis B virus (HBV) infection‐related liver diseases are immune‐mediated, including liver damage and viral control. It has been found that IL‐35 is detectable in peripheral CD4(+) T cells in chronic HBV‐infected patients, whereas it is undetectable in healthy individuals. There is growing evidence that cytokine‐mediated immune responses play a pivotal role in determining the clinical outcome during HBV infection. It is particularly important to investigate the effects of IL‐35 in the immunopathogenesis of chronic HBV infection. In this study, the recent understanding of this issue is discussed. Interleukin (IL)-35 is a recently identified heterodimeric cytokine that belongs to the IL-12 cytokine family, which is composed of the subunits of IL-27 β chain Epstein-Barr virus (EBV)-induced gene 3 (Ebi3) and IL-12 α chain p35. 1-3 IL-35 was first reported as Ebi3-p35 heterodimer at the 13th International Congress of Immunology in Rio de Janeiro, Brazil. 1, 2 In this study, we focused on the studies investigating the characteristics of IL-35 and its association with chronic hepatitis B virus (HBV) infection. IL-12 cytokine family, including IL-12, IL-23, IL-27 and IL-35, is the only family consisting of heterodimeric cytokines. [1] [2] [3] [4] An important characteristic of the IL-12 family is its chain-sharing of the cytokines and receptors. 4, 5 The IL-12-related cytokines are heterodimeric proteins composed of two subunits, an α chain (p19, p28 or p35) and a β chain (p40 or Ebi3). 4, 6 For example, IL-12 is composed of p35 and p40 subunits, whereas p40 binds to p19 to form IL-23 and Ebi3 binds to p28 to form IL-27. 7, 8 The IL-12 family consists of five different subunits: IL-12 receptor β1 (IL-12Rβ1), IL-12 receptor β2 (IL-12Rβ2), IL-23 receptor (IL-23R), IL-27 receptor (IL-27R, also known as WSX-1) and gp130. 3, 4, 9, 10 The receptors of IL-12 family also follow this chain-sharing character with several cytokines using the same receptor chains. 4, 5, 11 IL-12Rβ1 and IL-12Rβ2 form the receptor for IL-12, and that for IL-23 is composed of IL-12Rβ1 and IL-23R, while IL-27R and gp130 form the receptor for IL-27, and the receptor for IL-35 is composed of gp130 and IL-12Rβ2. 4, 9 Unusually, IL-35 also has another two receptors, that is, the homodimers of IL-12Rβ2-IL-12Rβ2 and gp130-gp130. 9 The Just Another Kinase (JAK)-Signal Transducers and Activator of Transcription (STAT) family consists of the downstream signal transduction pathway of these IL-12 receptors. 3, 11 Ebi3, which was first identified in EBV-infected B lymphoblastoid cell lines, is a homologue to IL-12 p40. 12 It has been reported that Ebi3 can bind the p35 subunit to form a heterodimeric hematopoietin by transfecting p35 and Ebi3 to cells in vitro. 13 In 2007, the Ebi3-p35 heterodimer was constructed, purified and identified as a cytokine in vitro, 1,2 and it was then officially named IL-35 by the International Union of Immunological Societies Subcommittee on Interleukin Nomenclature and the Human Genome Organisation (HUGO) Gene Nomenclature Committee. 14 Subsequently, IL-35 was reported to be secreted by fork-head box protein 3 (Foxp3) + regulatory T (Treg) cells as an inhibitory cytokine. 1 Besides Treg cells, activated dendritic cells (DCs), macrophages, endothelial cells and aortic smooth muscle cells also express IL- 35. 4,15-20 Since this discovery, biological function of IL-35 has been gradually illuminated during the recent years. IL-35 has been determined as a crucial cytokine of the IL-12 family. Despite the common structures of the cytokines and receptors as well as the downstream signaling components, the biological activities of the IL-12 family members are, to some extent, quite diverse. 3, 21 A consensus has been reached that IL-12 and IL-23 are mainly proinflammatory and pro-stimulatory cytokines that play vital roles in the differentiation of T helper (Th) 1 and Th17 cells, respectively. [22] [23] [24] And IL-27 is an immune-regulatory cytokine with both proinflammatory and antiinflammatory effects. 3, 4, 21, 22, [24] [25] [26] However, biological activity of the newly identified IL-35 is distinctive. Strictly speaking, IL-35 is a potential immunosuppressive cytokine produced by Treg cells and the recently reported regulatory B (Breg) cells. 3, 4, 9, 10, 18, 21, [27] [28] [29] [30] Treg cells are a special subset of T cells that are indispensable in regulating immune-mediated diseases such as autoinflammatory diseases, tumorigenesis and certain infections. The naturally occurring thymusderived CD4 + Treg cells are named as natural Treg (nTreg) cells. [31] [32] [33] The small population of nTreg cells in the subgroup of CD4 + T cells have the ability to maintain immune homeostasis through in vivo conversion of non-Treg cells to suppressive cells, a process called 'infectious tolerance'. 18, 34 Foxp3 + Treg cells are important regulators for infectious tolerance via their ability to convert conventional CD4 + Foxp3 − T cells into induced Treg (iTreg) cells directly by the production of suppressive cytokines, such as IL-10, transforming growth factor (TGF)-β or IL-35, or via DCs indirectly. 18, [34] [35] [36] [37] [38] Type 3 Treg (Tr3) and type 1 Treg (Tr1) cells have already been reported according to the cytokines that induce them with potently suppressive biological activity both in vitro and in vivo. 34, [39] [40] [41] [42] Conventional human or mouse T cells treated with the inhibitory cytokine IL-35 can generate a new type of iTreg cells that are different from TGF-β-or IL-10induced iTreg cells. IL-35-induced Treg cells are named iTr35 cells, which mediates the immunosuppressive function via IL-35 but not via inhibitory TGF-β or IL-10. 18 Unusually, the transcription factor Foxp3 is not expressed or required by the iTr35 cells. 18 Most recently, Shen et al. 27 have found that in autoimmune and infectious diseases, IL-35-secreting B cells function as crucial mediators in the negative regulation of immunity, and mice lacking IL-35 expression in B cells did not recover from experimental autoimmune encephalomyelitis only, which is a T cellmediated demyelinating autoimmune disease. However, these mice showed obviously improved resistance to infection with intracellular bacterial pathogen (Salmonella enterica serovar Typhimurium) compared with the mice with wild-type B cells. Wang et al. 28 29 it can switch off inflammation in rodent models of autoimmunity, whereas its absence in B cells enhanced their survival after infected with pathogens, indicating the potential therapeutic value of IL-35 targeting human autoimmune and infectious diseases. 29 The two studies have now taken the investigation of IL-35 to a new height. Chronic HBV infection is a leading cause of liver fibrosis, cirrhosis and even hepatocellular carcinoma, contributing to a major health threat and major economic burden in the world, despite the significant progress in vaccinations and antiviral therapy during the past decades. 44 It is estimated that two billion people worldwide have been infected, and 350-400 million are chronic HBV carriers. 45 In the 2010 Global Burden of Disease study, HBV infection ranked in the top health priorities in the world and was the 15th leading cause of death (786 000 deaths per year). 46 As HBV is a non-cytopathic virus, both HBV-related liver damage and viral control are immune-mediated. The natural history of chronic hepatitis B is generally divided into four phases: the immune tolerant phase, the immune clearance phase, the low replicative or inactive carrier stage and the reactivation phase. [47] [48] [49] There is growing evidence that cytokine-mediated immune responses play an important role in determining clinical outcomes during HBV infection. 44, [50] [51] [52] [53] [54] As an immunosuppressive cytokine, the predominant mechanism of suppression associated with the activity of IL-35 is its ability to inhibit T cell differentiation and effector functions. IL-35 plays a critical role in a variety of diseases, such as inflammatory bowel disease, 55-57 T cell-dependent colitis, 58 central nervous system demyelination, 59 smoking-related lung inflammation, 60 autoimmune diabetes, 61 coronary artery diseases, 62 autoimmune encephalomyelitis, 63 Based on the abovementioned studies on other immune-mediated diseases, there is abundant reason to believe that IL-35 might play a pivotal role in the immunopathogenesis of HBV infection and its related liver diseases, especially in the development of the immune tolerant phase and persistent chronic HBV infection. However, few studies have focused on the association between IL-35 and HBV infection so far. Thus, more studies are needed to elucidate the roles of IL-35 in HBV infection and its related lesions. In the field of viral hepatitis and liver diseases, Langhans et al. 81 have reported that the core antigen of hepatitis C virus (HCV) could induce the generation of a relatively high level of HCV core-specific Treg cells in patients with chronic hepatitis C. These HCV corespecific Treg cells could suppress the reporter T cells via the production of IL-35 and IL-10, 81 indicating a potential ability of IL-35 to inhibit virus-specific T cell responses that lead to persistent chronic HCV infection. Liu et al. 82 have provided the first research data that IL-35 is detectable in circulating CD4 + T cells in chronic HBV-infected patients, whereas it is undetectable in healthy controls. Liu et al. have showed that both the mRNA expression of Ebi3/p35 and the protein secretion of IL-35 is detectable in circulating CD4 + T cells in patients with chronic hepatitis B, suggesting that HBV could also act as an inducer for the CD4 + T cells to initiate IL-35 secretion. 82 In a study on primary biliary cirrhosis, Tsuda et al. 83 deleted the gene encoding the IL-12p35 subunit from dominantnegative TGF-β receptor type II (dnTGF-βRII) mice, which resulted in an IL-12p35(-/-) dnTGFβRII strain. They found that there was a strikingly high frequency (>50%) of liver fibrosis in the p35 −/− dnTGF-βRII mice, suggesting a possible correlation between IL-35 and liver fibrosis. Wang et al. 84 investigated the changes in the expression of IL-35 in patients with liver cirrhosisrelated portal hypertension complicated with esophageal variceal bleeding and splenomegaly before and after phased joint intervention (surgical intervention for treating the complications of decompensated liver cirrhosis), showing that the circulating concentrations of IL-35 were obviously reduced the efficient surgical intervention, and serum IL-35 levels were positively correlated with total bilirubin levels and international normalized ratio but was negatively correlated with albumin levels. This indicated that IL-35 might be correlated with the deterioration of liver cirrhosis. In conclusion, IL-35, a recently identified cytokine of the IL-12 family, can induce the generation of iTr35 cells and Breg cells, which function as an immunosuppressive factor in immune-mediated diseases such as With further advances in the understanding of IL-35 and its immunosuppressive mechanisms, it will be possible to design targeted immunotherapies and antivirus approaches to modulate the immune response for controlling persistent chronic HBV infection or deterioration in liver diseases. The inhibitory cytokine IL-35 contributes to regulatory T-cell function IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells IL-12 family cytokines: immunological playmakers Interleukin-35: odd one out or part of the family? Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily The IL-12 family of cytokines in infection, inflammation and autoimmune disorders Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4 + T cells The composition and signaling of the IL-35 receptor are unconventional Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance Interpreting mixed signals: the cell's cytokine conundrum A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin Interleukin is as interleukin does Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3 Human CD4 + CD25 + Foxp3 + regulatory T cells do not constitutively express IL-35 Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance IL-35-mediated induction of a potent regulatory T cell population IL-35 is a novel responsive anti-inflammatory cytokine -a new system of categorizing anti-inflammatory cytokines Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC Interleukin-12 family cytokines and sarcoidosis New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions IL-12 and IL-23: master regulators of innate and adaptive immunity Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines Regulation of immune responses by interleukin-27 IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases Interleukin-35 induces regulatory B cells that suppress autoimmune disease Interleukin-35 takes the 'B' line Interleukin-35: the future of hyperimmune-related diseases? A function for interleukin 2 in Foxp3-expressing regulatory T cells Foxp3-dependent programme of regulatory T-cell differentiation Control of regulatory T cell development by the transcription factor Foxp3 The battle against immunopathology: infectious tolerance mediated by regulatory T cells Natural versus adaptive regulatory T cells From vanilla to 28 flavors: multiple varieties of T regulatory cells The development and function of regulatory T cells Regulatory ripples Interleukin-10-secreting type 1 regulatory T cells in rodents and humans Conversion of peripheral CD4 + CD25 − naive T cells to CD4 + CD25 + regulatory T cells by TGF-β induction of transcription factor Foxp3 A CD4 + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis Regulation of immune responses by T cells Utilizing regulatory T cells against rheumatoid arthritis Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study Hepatitis B virus infection Hepatitis B virus infection Immunology of hepatitis B virus and hepatitis C virus infection Hepatitis B: the virus and disease Update on hepatitis B virus infection Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection The host-pathogen interaction during HBV infection: immunological controversies New insight in the pathobiology of hepatitis B virus infection Immunosuppression in patients with chronic hepatitis B Immunopathogenesis of chronic hepatitis B IL-35 stimulation of CD39 + regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10 Interleukin-35 enhances Lyme arthritis in Borreliavaccinated and -infected mice The possible role of the novel cytokines IL-35 and IL-37 in inflammatory bowel disease Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis Use of cytokine immunotherapy to block CNS demyelination induced by a recombinant HSV-1 expressing IL-2 Erythromycin enhances CD4 + Foxp3 + regulatory T-cell responses in a rat model of smoke-induced lung inflammation Prevention of autoimmune diabetes by ectopic pancreatic β-cell expression of interleukin-35 Decreased plasma IL-35 levels are related to the left ventricular ejection fraction in coronary artery diseases Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis Human prostate tumor antigen-specific CD8 + regulatory T cells are inhibited by CTLA-4 or IL-35 blockade IL-35: a potential target for the treatment of atherosclerosis Human placental trophoblasts express the immunosuppressive cytokine IL-35 Possible roles of IL-12-family cytokines in rheumatoid arthritis Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27 Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice Epstein-Barr virus-induced gene 3 negatively regulates neuroinflammation and T cell activation following coronavirus-induced encephalomyelitis Assessing the role of IL-35 in colorectal cancer progression and prognosis Aberrant expression of regulatory cytokine IL-35 and pattern recognition receptor NOD2 in patients with allergic asthma The expression of a novel anti-inflammatory cytokine IL-35 and its possible significance in childhood asthma Decreased concentration of IL-35 in plasma of patients with asthma and COPD Circulating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment program Circulating IL-35 in pancreatic ductal adenocarcinoma patients IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: Evidence for a role as an autocrine growth factor Dendritic cells decreased the concomitant expanded Tregs and Tregs related IL-35 in cytokine-induced killer cells and increased their cytotoxicity against leukemia cells The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia Regulatory T-cell-associated cytokines in systemic lupus erythematosus Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C Detectable expression of IL-35 in CD4 + T cells from peripheral blood of chronic hepatitis B patients Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice Effects of phased joint intervention on IL-35 and IL-17 expression levels in patients with portal hypertension